Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Patients Undergoing Laparoscopic Hepatectomy

A single-center, randomized, double-blind, placebo-controlled trial design will be adopted to investigate whether Anruikefon can significantly reduce the consumption of sufentanil via PCIA pumps within 48 hours postoperatively compared with placebo.

Inclusion Criteria: * Aged ≥ 18 years; * American Society of Anesthesiologists (ASA) physical status classification I-III; * Body mass index (BMI): 18 kg/m² ≤ BMI ≤ 30 kg/m²; * Patients scheduled to undergo laparoscopic hepatectomy under general anesthesia with estimated operation duration ≤ 5 hours; * Agree to participate in this trial and voluntarily sign the informed consent form. Exclusion Criteria: * Patients with a history of severe cardiopulmonary disease, neuropsychiatric disorders, digestive system diseases, chronic dizziness or vestibular dysfunction; * Patients undergoing emergency surgery or trauma patients; * Intraoperative conversion to open laparotomy; * History of abdominal surgery within the past 3 months; * Patients undergoing liver transplantation or with metastasis to other organs; * Patients requiring synchronous resection of organs other than the gallbladder, extrahepatic bile ducts and intestines due to intraoperative clinical needs; * Severe renal dysfunction (estimated glomerular filtration rate \